Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
salmeterol xinafoate + fluticasone propionate (Sandoz)
- Development stage
- Unknown
- Lead developer
- Sandoz
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
This is a fixed-dose combination therapy consisting of salmeterol xinafoate, a long-acting beta2-adrenergic agonist (LABA), and fluticasone propionate, an inhaled corticosteroid (ICS). It is indicated for the long-term maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD). Salmeterol provides bronchodilation by selectively stimulating beta2-adrenoceptors in the lungs, while fluticasone propionate exerts potent anti-inflammatory effects within the airways. This specific formulation, associated with Novartis's Sandoz division, is typically delivered via the Forspiro (also known as Girohaler) dry powder inhaler. In clinical trials, it is frequently used as an active comparator for newer respiratory therapies like the QVM149 triple combination.
- Brand names
- AirFluSal ForspiroAirFluSalSalmeterol/Fluticasone Sandoz
- Other names
- Salmeterol/FluticasoneSFC
02
Targets
GR (Glucocorticoid receptor)ADRB2 (β2)
Beyond the preview
Go deeper on salmeterol xinafoate + fluticasone propionate (Sandoz).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on salmeterol xinafoate + fluticasone propionate (Sandoz).